| Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. | |
| | |
MedLine Citation:
|
PMID: 21181319 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Efficacy of a continuous high-dose intravenous infusion of esomeprazole, followed by an oral regimen after successful endoscopic therapy for peptic ulcer bleeding (PUB) was established in the PUB study (ClinicalTrials. gov identifier: NCT00251979). Mortality rates and detailed safety and tolerability results from this study are reported here. METHODS: This was a double-blind, randomized study in patients ≥18 years with overt signs of upper gastrointestinal bleeding, following endoscopic diagnosis of a single gastric or duodenal ulcer (≥5 mm) with stigmata indicating current/ recent bleeding (Forrest class Ia, Ib, IIa, or IIb). Postendoscopic hemostasis, patients received intravenous esomeprazole (80 mg/30 minutes, then 8 mg/hour for 71.5 hours) or placebo. Postinfusion, all patients received open-label oral esomeprazole 40 mg once daily for 27 days. Mortality rates were analyzed using Fisher's exact test; other safety variables were analyzed descriptively. RESULTS: A total of 767 patients were randomized; 764 comprised the safety analysis set (375 patients received esomeprazole, 389 placebo). Baseline characteristics were similar across the two treatment groups. Three deaths from the esomeprazole treatment group and eight from the placebo group occurred during the trial (0.8% versus 2.1%; P=0.22). From these 11 all-cause deaths, one (esomeprazole group; rebleeding from duodenal ulcer) occurred during the 72-hour intravenous treatment phase. Adverse event (AE) frequency was similar for the two groups over the intravenous treatment phase (esomeprazole, 39.2%; placebo, 41.9%), with gastrointestinal disorders being most commonly reported (12.3% and 19.8%, respectively). Serious AEs were mostly related to bleeding events. Infusion-site reactions (mild, transient) were reported in 4.3% of esomeprazole-treated patients versus 0.5% of placebo patients. These did not lead to treatment discontinuation. CONCLUSION: Esomeprazole, given as a continuous high-dose intravenous infusion followed by an oral regimen after successful endoscopic therapy for PUB, was well tolerated, with no apparent safety concerns from either the high-dose intravenous treatment or oral phases. |
| | |
Authors:
|
Ernst J Kuipers; Joseph J Y Sung; Alan Barkun; Joachim Mössner; Dennis Jensen; Robert Stuart; James Y W Lau; Henrik Ahlbom; Tore Lind; Jan Kilhamn |
Related Documents
:
|
16434659 - Natural history of type a niemann-pick disease: possible endpoints for therapeutic trials. 20400339 - Distal biceps tendon tears in women. 6507079 - Closed treatment of achilles tendon rupture. 8169369 - Flexor tendon repair in zone ii with a new suture technique and an early mobilization p... 19643289 - Long-term follow-up of basal joint resection arthroplasty of the thumb with transfer of... 15157019 - Acellular and glutaraldehyde-preserved tendon allografts for reconstruction of superfic... 84259 - Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome... 9864869 - Prostate laser operation--the cheapest therapy? 872 cases. 18493269 - Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-12-15 |
Journal Detail:
|
Title: Advances in therapy Volume: 28 ISSN: 1865-8652 ISO Abbreviation: Adv Ther Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-03-04 Completed Date: 2011-07-27 Revised Date: 2013-01-31 |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 150-9 Citation Subset: T |
Affiliation:
|
Department of Gastroenterology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. e.j.kuipers@erasmusmc.nl |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00251979 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Aftercare / methods Aged Aged, 80 and over Dosage Forms Double-Blind Method Esomeprazole Sodium* / administration & dosage, adverse effects Female Hemostasis, Endoscopic* Humans Infusions, Intravenous Male Middle Aged Monitoring, Physiologic Peptic Ulcer / complications*, mortality, physiopathology Peptic Ulcer Hemorrhage* / etiology, mortality, physiopathology, therapy Proton Pump Inhibitors / administration & dosage, adverse effects Recurrence / prevention & control Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Dosage Forms; 0/Proton Pump Inhibitors; L2C9GWQ43H/Esomeprazole Sodium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on trea...
Next Document: Cell therapy for cardiovascular disease: a comparison of methods of delivery.